Integrated Generics, Inc. v. Bowen

678 F. Supp. 1004, 1988 U.S. Dist. LEXIS 1007, 1988 WL 9819
CourtDistrict Court, E.D. New York
DecidedFebruary 9, 1988
DocketCV 87-2032
StatusPublished
Cited by12 cases

This text of 678 F. Supp. 1004 (Integrated Generics, Inc. v. Bowen) is published on Counsel Stack Legal Research, covering District Court, E.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Integrated Generics, Inc. v. Bowen, 678 F. Supp. 1004, 1988 U.S. Dist. LEXIS 1007, 1988 WL 9819 (E.D.N.Y. 1988).

Opinion

MEMORANDUM AND ORDER

WEXLER, District Judge.

In this action plaintiff Integrated Generics, inc. (“Integrated Generics” or the “Company”) challenges certain procedures allegedly adopted by companies charged with the responsibility of processing and paying certain Medicare claims. Plaintiff also alleges that the government has violated statutory, regulatory and constitutional mandates in the handling of the Company’s Medicare claims. Declaratory and injunctive relief is sought prohibiting the defendants from continuing to carry out the allegedly illegal course of conduct. In addition, plaintiff seeks the payment of money that is allegedly being withheld pursuant to defendant’s unlawful practice.

Named as defendants are the Secretary of Health and Human Services (the “Secretary”), the Director of Operations for the Health Care Financing Administration, the Medical Operations Coordinator for Empire Blue Shield of New York and a Special Agent of the Office of the Inspector General of the Department of Health and Human Services. Each defendant is named solely in his official capacity.

Presently before the Court is a motion filed on behalf of all defendants to dismiss the complaint for lack of subject matter jurisdiction. In the alternative, defendants seek a stay of this action pending the outcome of closely related grand jury proceedings. For the reasons that follow, the motion to dismiss is denied. Because the issues in this case are certainly closely related and, possibly, identical to those likely to be aired in the course of defendants’ investigation of the plaintiff, this case is stayed pending the resolution of the grand jury investigation.

I. The Relevant Statutory and Regulatory Scheme

A. The Statutory Administration of Benefits

At issue here are procedures used in the administration of the Health Insurance for the Aged and Disabled Program, otherwise known as Medicare. 42 U.S.C. § 1395 et seq. The Medicare program is divided into two parts. Part A of the program deals with hospitalization benefits. 42 U.S.C. § 1395c-1395i. Part B, the part directly at issue in this lawsuit, is entitled “Supplementary Medical Insurance For Aged and Disabled” and covers, in general, expenses equal to 80% of the reasonable charges for services such as laboratory tests and x-rays. See 42 U.S.C. §§ 1395j-1395w.

To provide for the efficient and convenient administration of Part B benefits, Congress has authorized the Secretary to *1006 enter into contracts with companies, known as “carriers,” to perform certain functions on behalf of the Secretary. 42 U.S.C. § 1395u. Carriers are authorized to, inter alia, determine the rates and amounts of payments made to providers of services, receive and account for funds in making payments to providers and audit the records of providers to ensure that proper payments are made. 42 U.S.C. § 1395u(a)(l).

B. Regulations Governing a Provider’s Suspected Misconduct

Several regulations have been promulgated that are addressed to the proper procedures to be followed where fraud or overpayment in connection with the carrier/provider scheme is suspected or proven. Certain regulations provide for the temporary suspension of provider payments while others provide for the more extreme sanction of exclusion from participation in the Medicare program. These regulations allow for action to be taken either by carriers or by the Office of the Inspector General of the Department of Health and Human Services (the “OIG”).

i. Suspension by Carriers

Those regulations governing action by the carrier give carriers the right to suspend payments where the carrier has reliable evidence of overpayment or fraud. See generally 42 C.F.R. § 405.370. Although the applicable regulations are addressed to the carrier’s knowledge of suspected misconduct, they do not discuss the source of that knowledge. Thus the regulations do not preclude carrier suspension based on information obtained by the government and later communicated to the carrier.

Where payment is suspended due to suspected overpayment, the carrier must notify the provider of the intention to suspend payments and of the reasons for the suspension. Such notification must take place prior to the actual suspension. 42 C.F.R. § 405.371(a). After notification, the provider is given the opportunity to submit a statement and evidence showing why the suspension should not be put into effect. Id. In cases where the carrier has reliable evidence of provider fraud or misrepresentation (as opposed to overpayment) the aforementioned notice requirements do not apply. See 42 C.F.R. § 405.371(b). Instead, notice to a provider suspected of fraud or misrepresentation may follow the actual suspension of payments. Id.

Whatever the ground cited by the carrier in support of the decision to suspend payments, the suspension amounts to nothing more than a withholding of payments pending the outcome of an investigation. The provider is not precluded from participation in the Medicare program and claims continue to be processed and credited to the provider’s account. If it is ultimately found that neither fraud nor overpayment exists, the withheld funds are turned over to the provider.

ii. Exclusion by the OIG

42 C.F.R. Part 1001 (“Part 1001”) is addressed to actions taken by the OIG where there is evidence of provider fraud or abuse. See 42 C.F.R. § 1001.3. Pursuant to Part 1001, when the OIG determines that certain enumerated fraudulent activities have taken place, the OIG has the power to exclude or terminate a provider from participation in the Medicare program. See 42 C.F.R. § 1001.101(a); 42 C.F.R. § 1001.201. If the OIG intends to take such action, it must first comply with the procedures set forth in 42 C.F.R. § 1001.05.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

in Re: Thomas Lytle and Ellen Lytle
Court of Appeals of Texas, 2015
Javier H. v. Garcia-Botello
218 F.R.D. 72 (W.D. New York, 2003)
Isernio v. U.S.I. Holdings Corp.
182 Misc. 2d 121 (New York Supreme Court, 1999)
Twenty First Century Corp. v. LaBianca
801 F. Supp. 1007 (E.D. New York, 1992)
Downtown Medical Center v. Bowen
944 F.2d 756 (Tenth Circuit, 1991)
Goodman v. Sullivan
712 F. Supp. 334 (S.D. New York, 1989)
Neiman v. Secretary of the Department of Health
722 F. Supp. 950 (E.D. New York, 1988)
Kuritzky v. Blue Shield of Western New York, Inc.
850 F.2d 126 (Second Circuit, 1988)
Kuritzky v. Blue Shield Of Western New York
850 F.2d 126 (Second Circuit, 1988)

Cite This Page — Counsel Stack

Bluebook (online)
678 F. Supp. 1004, 1988 U.S. Dist. LEXIS 1007, 1988 WL 9819, Counsel Stack Legal Research, https://law.counselstack.com/opinion/integrated-generics-inc-v-bowen-nyed-1988.